Aquestive Therapeutics (AQST) Revenue & Revenue Breakdown
Aquestive Therapeutics Revenue Highlights
Latest Revenue (Y)
$50.58M
Latest Revenue (Q)
$13.54M
Main Segment (Y)
Manufacture and Supply Revenue
Main Geography (Y)
UNITED STATES
Aquestive Therapeutics Revenue by Period
Aquestive Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $50.58M | 6.09% |
| 2022-12-31 | $47.68M | -6.20% |
| 2021-12-31 | $50.83M | 10.87% |
| 2020-12-31 | $45.85M | -12.85% |
| 2019-12-31 | $52.61M | -21.98% |
| 2018-12-31 | $67.43M | 0.77% |
| 2017-12-31 | $66.92M | 29.22% |
| 2016-12-31 | $51.78M | - |
Aquestive Therapeutics generated $50.58M in revenue during NA 2023, up 6.09% compared to the previous quarter, and up 75.02% compared to the same period a year ago.
Aquestive Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $13.54M | -32.62% |
| 2024-06-30 | $20.10M | 66.76% |
| 2024-03-31 | $12.05M | -8.73% |
| 2023-12-31 | $13.21M | 1.57% |
| 2023-09-30 | $13.00M | -1.80% |
| 2023-06-30 | $13.24M | 18.92% |
| 2023-03-31 | $11.13M | 4.23% |
| 2022-12-31 | $10.68M | -6.81% |
| 2022-09-30 | $11.46M | -13.58% |
| 2022-06-30 | $13.27M | 8.11% |
| 2022-03-31 | $12.27M | 10.76% |
| 2021-12-31 | $11.08M | -16.63% |
| 2021-09-30 | $13.29M | -13.41% |
| 2021-06-30 | $15.35M | 37.97% |
| 2021-03-31 | $11.12M | 55.57% |
| 2020-12-31 | $7.15M | -13.45% |
| 2020-09-30 | $8.26M | -61.89% |
| 2020-06-30 | $21.68M | 147.29% |
| 2020-03-31 | $8.77M | -46.62% |
| 2019-12-31 | $16.42M | 32.22% |
| 2019-09-30 | $12.42M | 11.58% |
| 2019-06-30 | $11.13M | -11.98% |
| 2019-03-31 | $12.64M | -24.85% |
| 2018-12-31 | $16.82M | 26.81% |
| 2018-09-30 | $13.27M | -4.75% |
| 2018-06-30 | $13.93M | -40.51% |
| 2018-03-31 | $23.41M | 91.97% |
| 2017-12-31 | $12.20M | -55.08% |
| 2017-09-30 | $27.15M | 143.64% |
| 2017-06-30 | $11.14M | -32.21% |
| 2017-03-31 | $16.44M | - |
Aquestive Therapeutics generated $13.54M in revenue during Q3 2024, up -32.62% compared to the previous quarter, and up 102.27% compared to the same period a year ago.
Aquestive Therapeutics Revenue Breakdown
Aquestive Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Manufacture and Supply Revenue | $43.80M | $36.38M | $35.31M | $24.88M | $38.74M |
| Co-Development and Research Fees | $1.40M | $1.29M | $1.64M | $1.26M | $4.04M |
| License and Royalty Revenue | $5.38M | $2.35M | $5.38M | $14.05M | $6.96M |
| Proprietary Product Sales | - | $7.66M | $8.51M | $5.65M | $2.87M |
| Royalty | - | $-916.00K | $-1.10M | - | - |
Aquestive Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Manufacture and Supply Revenue (86.60%), License and Royalty Revenue (10.63%), and Co-Development and Research Fees (2.77%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacture and Supply Revenue | $10.67M | $10.52M | $11.00M | $11.41M | $11.64M | $9.76M | $8.92M | $8.41M | $9.87M | $9.17M | $7.69M | $10.45M | $10.66M | $6.51M | $4.80M | $5.90M | $7.26M | $6.92M | $14.00M | $9.15M |
| Manufactured Product, Other | $217.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License and Royalty Revenue | $2.16M | $1.13M | $1.87M | $1.10M | $1.48M | $919.00K | $917.00K | $376.00K | $552.00K | $506.00K | $380.00K | $328.00K | $2.36M | $373.00K | $328.00K | $12.93M | $426.00K | $557.00K | $1.36M | - |
| Co-Development and Research Fees | $492.00K | $403.00K | $335.00K | $490.00K | $124.00K | $453.00K | $254.00K | $395.00K | $241.00K | $403.00K | $218.00K | $523.00K | $456.00K | $394.00K | $1.18M | - | - | - | - | - |
| Proprietary Product Sales | - | - | - | - | - | - | $589.00K | $2.28M | $2.60M | $2.19M | $2.79M | $1.99M | $1.91M | $1.58M | $682.00K | - | - | - | - | - |
| Royalty | - | - | - | - | - | - | $-13.00K | $-25.00K | - | - | - | - | - | - | - | - | - | - | - | - |
Aquestive Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Manufacture and Supply Revenue (78.80%), License and Royalty Revenue (15.97%), Co-Development and Research Fees (3.63%), and Manufactured Product, Other (1.60%).
Aquestive Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $37.10M | $39.92M | $42.86M | - | - |
| Non-US | $13.48M | $7.76M | $7.97M | $4.89M | $4.32M |
| United States | - | - | - | $40.96M | $48.29M |
Aquestive Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (73.35%), and Non-US (26.65%).
Quarterly Revenue by Country
| Country | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Dec 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $10.53M | $10.43M | $11.73M | $9.89M | $7.31M | $8.16M | $8.51M | $9.08M | $11.26M | $11.08M | $9.37M | $10.53M | $13.11M | - | - | - | - | - |
| Non-US | $3.01M | $1.63M | $1.47M | $3.11M | $5.93M | $2.97M | $2.18M | $2.38M | $2.01M | $1.19M | $1.71M | $2.76M | $2.24M | $1.69M | $1.81M | - | - | - |
| United States | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.46M | $14.61M | $15.51M | $12.48M | $13.38M |
Aquestive Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (77.74%), and Non-US (22.26%).
Aquestive Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALKS | Alkermes | $1.66B | $378.14M |
| LNTH | Lantheus | $1.30B | $378.73M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $188.82M |
| ANIP | ANI Pharmaceuticals | $486.82M | $148.33M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $91.59M |
| ORGO | Organogenesis | $433.14M | $115.18M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $79.34M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| AQST | Aquestive Therapeutics | $50.58M | $13.54M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| EVOK | Evoke Pharma | $5.18M | $2.65M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| ACRX | Talphera | $651.00K | $117.00K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |